At the University of Edinburgh, researchers have turned the body's own immune cells into healers—transforming ordinary white blood cells into biological repairmen capable of reversing the damage of advanced liver disease. This breakthrough macrophage-based cell therapy, tested in a rigorous four-year clinical trial called MATCH, offers genuine hope to patients facing cirrhosis and liver failure, conditions that have historically condemned them to transplant waiting lists or early death.
Liver disease remains a brutal global killer. Cirrhosis scarring progressively destroys the liver's legendary ability to regenerate itself, until the organ simply fails. For decades, liver transplantation was the only lifeline—but it's a lifeline most patients never reach. Donor organs are desperately scarce, transplants cost a fortune, and strict medical criteria exclude many from eligibility. The result: thousands die waiting, their options exhausted. Researchers have long searched for an alternative, and now Professor Stuart Forbes and his team at Edinburgh's Institute for Regeneration and Repair have found one.
The therapy works by extracting monocytes from a patient's own blood, coaxing them in the laboratory to mature into specialized macrophages—immune cells that act as the body's demolition and repair crew. When reintroduced into the patient, these cells migrate to the scarred liver and get to work: they break down fibrotic scar tissue, quiet the chronic inflammation that fuels liver damage, and release growth factors that stimulate the regeneration of healthy liver cells. It's cellular medicine at its most elegant.
The MATCH trial enrolled 50 patients with advanced cirrhosis, randomly assigned to receive either macrophage therapy or standard medical care. The results were stark. After four years, 70 percent of those who received the cell therapy survived without needing a liver transplant. In the control group, only 40 percent achieved that milestone. Among the treated patients, there were zero transplants and eight deaths. The control group underwent five transplants and suffered nine deaths. Equally crucial: the macrophage therapy produced no serious side effects, a finding that speaks to both its tolerability and safety in medically fragile patients.
What makes this advance particularly significant is its durability. Many experimental cell therapies produce brief, fading benefits. These macrophages deliver sustained biological effects, rewriting the inflammatory landscape of the liver and actively driving tissue repair long after infusion. Blood biomarkers confirm the mechanism at work—markers of reduced inflammation and improved liver function rise measurably after treatment, providing the molecular proof that repair is genuinely occurring.
This is not laboratory curiosity. Professor Forbes and his collaborators, working with the Scottish National Blood Transfusion Service and clinical centers across Scotland, have translated a decade of basic research into a therapy that now saves lives. A spinout company called Resolution Therapeutics, launched with support from Edinburgh Innovations, is advancing a refined version of the macrophage therapy called RTX001 through the ongoing EMERALD clinical trial, aiming to optimize and validate the approach for broader use.
For patients and families confronting advanced liver disease, the significance cannot be overstated. This therapy transforms a death sentence into a fighting chance—without the scarcity, cost, and eligibility barriers that make transplantation impossible for so many. The work from Edinburgh suggests that sometimes the best healer lies within the body itself, waiting only to be awakened.